Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

External preparation of simvastatin and application of external preparation

A technology for external preparations and simvastatin, which is applied in the field of external preparations of simvastatin, can solve the problems of pigmentation, repeated treatment, skin loss, etc., and achieves the effects of increasing aggregation concentration, reducing side effects, and avoiding side effects.

Active Publication Date: 2019-10-25
XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these treatments have different limitations and adverse reactions, such as skin loss, scarring, hyperpigmentation, hypopigmentation, repeated treatment, invasiveness and recurrence, etc.
In 40% of patients with eyelid xanthoma, the pathology found that the foam cells had reached the muscle layer of the skin, so physical and surgical resection is difficult to achieve good results
[0008] Although the skin lesions of CHILD syndrome and xanthomatosis are mostly benign, they both seriously affect the aesthetics and the psychology of the patients.
However, the current treatment methods have serious limitations and side effects, so no satisfactory treatment method has been found yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • External preparation of simvastatin and application of external preparation
  • External preparation of simvastatin and application of external preparation
  • External preparation of simvastatin and application of external preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] The present embodiment is 1% simvastatin emulsifiable cream, and formula is as follows:

[0055] Table 1 temporary preparation 1% simvastatin cream (specification: 20g / box)

[0056] product name quantity unit Simvastatin 50 gram stearic acid 573 gram Sodium dodecyl sulfate 10 gram Ethylparaben 5 gram Glyceryl monostearate 333 gram light liquid paraffin 104 ml Triethanolamine 10 ml distilled water 3265 ml glycerin 625 gram Laurocaprazine 25 ml Co-made 5000 gram

[0057] Preparation method: Take glyceryl monostearate, stearic acid, and light liquid paraffin, heat and melt, add ethyl paraben, stir to dissolve, and keep warm at about 80°C. Heat distilled water to boil, add sodium lauryl sulfate, simvastatin, glycerin, grind well, and keep warm at about 80°C. Filter the oil phase into the water phase, stir for 15 to 20 minutes, add triethanolamine and laurocaprazine, an...

Embodiment 2

[0059] The present embodiment is 2.5% simvastatin emulsifiable cream, and formula is as follows:

[0060] Table 2 temporary preparation 2.5% simvastatin cream (specification: 20g / box)

[0061]

[0062]

[0063] Preparation method: Take glyceryl monostearate, stearic acid, and light liquid paraffin, heat and melt, add ethyl paraben, stir to dissolve, and keep warm at about 80°C. Heat distilled water to boil, add sodium lauryl sulfate, simvastatin, glycerin, grind well, and keep warm at about 80°C. Filter the oil phase into the water phase, stir for 15 to 20 minutes, add triethanolamine and laurocaprazine, and continue stirring until it condenses to obtain the product.

Embodiment 3

[0065] The present embodiment is 5% simvastatin emulsifiable cream, and formula is as follows:

[0066] Table 3 temporary preparation 5% simvastatin cream (specification: 20g / box)

[0067] product name quantity unit Simvastatin 250 gram stearic acid 573 gram Sodium dodecyl sulfate 10 gram Ethylparaben 5 gram Glyceryl monostearate 333 gram light liquid paraffin 104 ml Triethanolamine 10 ml distilled water 3065 ml glycerin 625 gram Laurocaprazine 25 ml Co-made 5000 gram

[0068] Preparation method: Take glyceryl monostearate, stearic acid, and light liquid paraffin, heat and melt, add ethyl paraben, stir to dissolve, and keep warm at about 80°C. Heat distilled water to boil, add sodium lauryl sulfate, simvastatin, glycerin, grind well, and keep warm at about 80°C. Filter the oil phase into the water phase, stir for 15 to 20 minutes, add triethanolamine and laurocaprazine, a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of pharmaceutical preparations, in particular to an external preparation of simvastatin and an application of the external preparation. The external preparation is composed of simvastatin and pharmaceutically acceptable auxiliary materials. The preparation can effectively treat CHILD (congenital hemidysplasia with ichthyosiform erythroderma and limb defects) syndrome and xanthomatosis. The preparation has the advantages of convenient treatment, safety, low price, fat solubility, no trauma, easy observation of curative effect and low recurrence rate;high concentration of drugs in the target site of the skin increases the curative effect and reduces the systematic side effects of a simvastatin oral preparation; for patients with xanthomatosis whoare not suitable for or unwilling to be treated with oral lipid-lowering drugs for a long time, the effect of treating skin lesions is achieved, and adverse reactions caused by the absorption of thedrug system is avoided.

Description

technical field [0001] The invention relates to the technical field of pharmaceutical preparations, in particular to an external preparation of simvastatin and its application. Background technique [0002] CHILD (Congenital hemidysplasia with ichthyosiform erythroderma and limb defects) syndrome is a rare X-linked dominant genetic disease. It is characterized by congenital hemidysplasia with ichthyosis-like or verrucous hyperplasia-like skin lesions on the same side and limb deformities on the same side, and is fatal in males. The NSDHL gene on the Xq28 chromosome is the only causative gene of the disease found so far. The NSDHL gene encodes 3β-hydroxysteroid dehydrogenase, and mutations in this gene lead to disorders of cholesterol synthesis and accumulation of upstream toxic products. This local abnormality of lipid metabolism enables macrophages to phagocytose a large number of lipid droplets to form foam cells, eventually leading to the characteristic skin lesions of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K9/06A61K31/366A61P17/00A61P35/00A61P3/06
CPCA61K9/0014A61K9/06A61K31/366A61P17/00A61P35/00A61P3/06Y02A50/30
Inventor 姚智荣余霞
Owner XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com